# US 2013/0156777 A1 · Glipr1 inhibitors and therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156777 A1
- Document ID: US20130156777A1
- Status: Published application
- Kind: A1
- Application number: 13/606,866
- Filed: 2012-09-07
- Published: 2013-06-20
- Earliest claimed: 2011-09-12
- Inventors: Raymond A. Koski; Nathalie Bonafe; Oluwatoyin A. Asojo
- Web page: https://patentgrep.com/patent/US20130156777A1

## CPC

- C07K 16/3053: {Skin, nerves, brain}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Featured herein are unique epitopes of human glioma pathogenesis-related protein 1 (hGLIPR-1), nucleic acids encoding the same; inhibitors of the nucleic acids and polypeptides; as well as methods for treating certain cancers and viral infections in a subject by administering to the subject an effective amount of a GLIPR1 inhibitor.

## Claims

### Claim 1

A composition, which binds to a polypeptide selected from the group consisting of SEQ ID NOs: 1, 11, 13, 15, 17, 19, 21, 23 and 25.

### Claim 2 (depends on 1)

A composition of claim 1, which is a protein or a peptide.

### Claim 3 (depends on 1)

A composition of claim 1, which is an antibody.

### Claim 4 (depends on 1)

A composition of claim 1, which is an inhibitor of GLIPR1

### Claim 5 (depends on 2)

A pharmaceutical composition comprising an effective amount of a composition of claim 2 and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 1)

A composition of claim 1 conjugated to diagnostic, antiviral or anti-cancer agent.

### Claim 7 (depends on 2)

A method of inhibiting GLIPR1 activity in a cell comprising contacting the cell with a composition of claim 2.

### Claim 8 (depends on 7)

A method of claim 7, wherein the inhibitor binds GLIPR1 on the surface of cells.

### Claim 9 (depends on 7)

A method of claim 7, wherein the inhibitor binds GLIPR1 in lipid rafts on the surface of cells.

### Claim 10 (depends on 7)

A method claim 7, wherein the cell is a cancer cell or a virally infected cell.

### Claim 11 (depends on 7)

A method of claim 7, wherein GLIPR1 or AKT contributes to the cancer cell's growth.

### Claim 12 (depends on 7)

A method of claim 7, wherein GLIPR1 contributes to viral pathogenesis.

### Claim 13 (depends on 7)

A method of claim 7, wherein the inhibitor reduces matrix metalloproteinase-2 secretion.

### Claim 14 (depends on 7)

A method of claim 7, wherein the inhibitor reduces cell proliferation, migration or spheroid formation.

### Claim 15 (depends on 7)

A method of claim 7, wherein the inhibitor downregulates cell surface GLIPR1.

### Claim 16 (depends on 7)

A method of claim 7, wherein the inhibitor induces AKT cleavage.

### Claim 17 (depends on 5)

A method for treating or preventing a cancer in a subject, comprising administering to the subject a pharmaceutical composition of claim 5.

### Claim 18 (depends on 17)

A method of claim 17, wherein GLIPR1 or AKT contributes to the cancer cell's growth.

### Claim 19 (depends on 5)

A method for treating or preventing a viral infection in a subject, comprising administering to the subject a pharmaceutical composition of claim 5.

### Claim 20 (depends on 19)

A method of claim 19, wherein GLIPR1 contributes to viral pathogenesis.